Clinical Efficacy and Survival Analysis of Chidamide Combined with R-DHAP Regimen in the Treat-ment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
[Objective]To explore the efficacy of chidamide combined with R-DHAP regimen in the treatment of re-lapsed/refractory diffuse large B-cell lymphoma(DLBCL).[Methods]A total of 78 patients with relapsed/refractory DLBCL were selected and randomly divided into the observation group and the control group.The control group was treated with R-DHAP regimen,and the study group was treated with chidamide combined with R-DHAP regimen.The ECOG score,clinical efficacy,serum vascular endothelial growth factor(VEGF),β2-microglobulin(β2-MG)levels,adverse drug,and progression-free survival time reactions were compared between the two groups.[Results]After 3 courses of treatment,the ECOG scores of both groups were lower(P＜0.05),which the study group showed lower than the control group(P＜0.05).The objective remission rate of the observation group was higher than that of the control group(P＜0.05).After 3 courses of treatment,the levels of serum VEGF and β2-MG in both groups were lower than those before treatment(P＜0.05);And the levels of serum VEGF and β2-MG in the observation group were lower than those in the control group(P＜0.05).The incidence of adverse reactions in both groups was not statistically significant(P＞0.05).The median progression-free survival curves between the observation group and the control group was 20.60 months and 15.18 months,respectively,which was statistically significant difference(P＜0.05).[Conclusion]Chidamide combined with R-DHAP regimen in the treatment of patients with relapsed/refractory DLBCL can improve clinical symptoms and enhance the curative effect.It can reduce the levels of serum VEGF and β2-MG,prolong the survival time of patients,and it is safe and reliable.
万方数据
维普
